StockData
Elicio Therapeutics, Inc. logo

Elicio Therapeutics, Inc. (ELTX) stock

ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$1.43−0.05 (-3.38%)

Close on Nov 17, 2026Market cap $37.58MP/E –Yield –

Elicio Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Elicio Therapeutics's price to sales ratio was 4.6× on Jul 31, 2023, against 0.1× a year earlier. Over the last 3 years it ranged from 0.1× to 20.2×, with a median of 3.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Jul 31, 20234.6×+4.5
2022Dec 30, 20220.1×−3.1
2021Dec 31, 20213.2×–

More Elicio Therapeutics figures

See a number that looks wrong?